155 related articles for article (PubMed ID: 12855616)
1. Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study.
Repka T; Chiorean EG; Gay J; Herwig KE; Kohl VK; Yee D; Miller JS
Clin Cancer Res; 2003 Jul; 9(7):2440-6. PubMed ID: 12855616
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.
Parihar R; Nadella P; Lewis A; Jensen R; De Hoff C; Dierksheide JE; VanBuskirk AM; Magro CM; Young DC; Shapiro CL; Carson WE
Clin Cancer Res; 2004 Aug; 10(15):5027-37. PubMed ID: 15297404
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661.
Fleming GF; Meropol NJ; Rosner GL; Hollis DR; Carson WE; Caligiuri M; Mortimer J; Tkaczuk K; Parihar R; Schilsky RL; Ratain MJ
Clin Cancer Res; 2002 Dec; 8(12):3718-27. PubMed ID: 12473581
[TBL] [Abstract][Full Text] [Related]
4. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2.
Gennari R; Menard S; Fagnoni F; Ponchio L; Scelsi M; Tagliabue E; Castiglioni F; Villani L; Magalotti C; Gibelli N; Oliviero B; Ballardini B; Da Prada G; Zambelli A; Costa A
Clin Cancer Res; 2004 Sep; 10(17):5650-5. PubMed ID: 15355889
[TBL] [Abstract][Full Text] [Related]
5. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2.
Varchetta S; Gibelli N; Oliviero B; Nardini E; Gennari R; Gatti G; Silva LS; Villani L; Tagliabue E; Ménard S; Costa A; Fagnoni FF
Cancer Res; 2007 Dec; 67(24):11991-9. PubMed ID: 18089830
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L
Semin Oncol; 1999 Aug; 26(4 Suppl 12):78-83. PubMed ID: 10482197
[TBL] [Abstract][Full Text] [Related]
8. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
9. Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study.
Montemurro F; Choa G; Faggiuolo R; Sperti E; Capaldi A; Donadio M; Minischetti M; Salomone A; Vietti-Ramus G; Alabiso O; Aglietta M
Am J Clin Oncol; 2003 Feb; 26(1):95-7. PubMed ID: 12576933
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.
Jerusalem G; Fasolo A; Dieras V; Cardoso F; Bergh J; Vittori L; Zhang Y; Massacesi C; Sahmoud T; Gianni L
Breast Cancer Res Treat; 2011 Jan; 125(2):447-55. PubMed ID: 21107682
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab.
Mani A; Roda J; Young D; Caligiuri MA; Fleming GF; Kaufman P; Brufsky A; Ottman S; Carson WE; Shapiro CL
Breast Cancer Res Treat; 2009 Sep; 117(1):83-9. PubMed ID: 19051009
[TBL] [Abstract][Full Text] [Related]
13. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer.
Infante JR; Yardley DA; Burris HA; Greco FA; Farley CP; Webb C; Spigel DR; Hainsworth JD
Clin Breast Cancer; 2009 Feb; 9(1):23-8. PubMed ID: 19299236
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
Michalaki V; Fotiou S; Gennatas S; Gennatas C
Anticancer Res; 2010 Jul; 30(7):3051-4. PubMed ID: 20683054
[TBL] [Abstract][Full Text] [Related]
16. Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer.
Bianchi G; Albanell J; Eiermann W; Vitali G; Borquez D; Viganò L; Molina R; Raab G; Locatelli A; Vanhauwere B; Gianni L; Baselga J
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5944-51. PubMed ID: 14676119
[TBL] [Abstract][Full Text] [Related]
17. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients.
Beano A; Signorino E; Evangelista A; Brusa D; Mistrangelo M; Polimeni MA; Spadi R; Donadio M; Ciuffreda L; Matera L
J Transl Med; 2008 May; 6():25. PubMed ID: 18485193
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
19. Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.
Saura C; Bendell J; Jerusalem G; Su S; Ru Q; De Buck S; Mills D; Ruquet S; Bosch A; Urruticoechea A; Beck JT; Di Tomaso E; Sternberg DW; Massacesi C; Hirawat S; Dirix L; Baselga J
Clin Cancer Res; 2014 Apr; 20(7):1935-45. PubMed ID: 24470511
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
Goldenberg MM
Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
